Literature DB >> 18973061

Insulin resistance and high sensitivity C-reactive protein in migraine.

Baburhan Guldiken1, Sibel Guldiken, Muzaffer Demir, Nilda Turgut, Levent Kabayel, Hulya Ozkan, Emine Ozcelik, Armagan Tugrul.   

Abstract

BACKGROUND: A relationship between migraine and vascular disorders such as hypertension, stroke, and coronary ischemia has been recently reported. Insulin resistance and endothelial dysfunction, which commonly underlies these disorders, have not been widely investigated in migraine patients. In this study, we aimed to investigate the existence of insulin resistance and endothelial dysfunction, and their relationship to vascular risk factors in patients with migraine.
METHODS: We evaluated insulin resistance and high-sensitivity C-reactive protein (hs-CRP), a marker of endothelial dysfunction, in 60 migraine patients and 25 healthy control subjects. Multiple analysis of covariance test was used to adjust for known confounding factors that can influence insulin metabolism and endothelial function, such as obesity, blood pressure, and lipid parameters.
RESULTS: Insulin resistance, as measured homeostasis model assessment (HOMA)-R levels, was significantly higher in the migraine group (p<0.001). After adjustment for confounding variables, the relationship between migraine and the HOMA-R levels remained significant (p<0.001). The hs-CRP levels did not differ between the migraine and control groups.
CONCLUSIONS: Our data show that insulin resistance is present in migraine patients. Endothelial dysfunction is not found during the headache-free period. Further studies are needed to explain the role of insulin resistance in migraine pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18973061     DOI: 10.1017/s0317167100009100

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  8 in total

1.  Metabolic syndrome and insulin resistance in migraine.

Authors:  Sanjeev K Bhoi; Jayantee Kalita; Usha K Misra
Journal:  J Headache Pain       Date:  2012-01-26       Impact factor: 7.277

2.  Non-alcoholic fatty liver disease in patients with migraine.

Authors:  Asuman Celikbilek; Mehmet Celikbilek; Aylin Okur; Serkan Dogan; Elif Borekci; Mustafa Kozan; Sebnem Gursoy
Journal:  Neurol Sci       Date:  2014-04-23       Impact factor: 3.307

3.  Migraine and risk of incident diabetes in women: a prospective study.

Authors:  Rebecca C Burch; Pamela M Rist; Anke C Winter; Julie E Buring; Aruna D Pradhan; Elizabeth W Loder; Tobias Kurth
Journal:  Cephalalgia       Date:  2012-07-17       Impact factor: 6.292

4.  The serum level of inflammatory markers in chronic and episodic migraine: a case-control study.

Authors:  Fahimeh Martami; Soodeh Razeghi Jahromi; Mansoureh Togha; Zeinab Ghorbani; Maryam Seifishahpar; Atoosa Saidpour
Journal:  Neurol Sci       Date:  2018-07-15       Impact factor: 3.307

5.  Evaluation of carotid intima-media thickness in children with migraine: a marker of subclinical atherosclerosis.

Authors:  Hatice Gamze Poyrazoglu; Umit Erkan Vurdem; Alev Arslan; Salih Uytun
Journal:  Neurol Sci       Date:  2016-07-01       Impact factor: 3.307

6.  Soluble CD40 ligand and prolactin levels in migraine patients during interictal period.

Authors:  Sibel Guldiken; Baburhan Guldiken; Muzaffer Demir; Levent Kabayel; Hulya Ozkan; Nilda Turgut; Remziye Hunkar; Selahattin Kat
Journal:  J Headache Pain       Date:  2011-02-18       Impact factor: 7.277

7.  High sensitivity C-reactive protein and cerebral white matter hyperintensities on magnetic resonance imaging in migraine patients.

Authors:  Aynur Yilmaz Avci; Hatice Lakadamyali; Serap Arikan; Ulku Sibel Benli; Munire Kilinc
Journal:  J Headache Pain       Date:  2015-01-16       Impact factor: 7.277

Review 8.  Migraine and body mass index categories: a systematic review and meta-analysis of observational studies.

Authors:  Raffaele Ornello; Patrizia Ripa; Francesca Pistoia; Diana Degan; Cindy Tiseo; Antonio Carolei; Simona Sacco
Journal:  J Headache Pain       Date:  2015-03-28       Impact factor: 7.277

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.